Last reviewed · How we verify
Placebo (for Rotarix dose 2)
Placebo is an inert substance with no active pharmacological mechanism; it serves as a control comparator in clinical trials.
Placebo is an inert substance with no active pharmacological mechanism; it serves as a control comparator in clinical trials. Used for Control arm in Rotarix (rotavirus vaccine) dose 2 clinical trial.
At a glance
| Generic name | Placebo (for Rotarix dose 2) |
|---|---|
| Sponsor | University of Vermont |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo has no direct molecular or therapeutic mechanism of action. In clinical trials, it is used as a control arm to measure the efficacy of an active drug by comparison and to account for placebo effect and natural disease progression. Any observed effects in the placebo group are attributed to psychological factors, natural recovery, or trial design artifacts rather than pharmacological activity.
Approved indications
- Control arm in Rotarix (rotavirus vaccine) dose 2 clinical trial
Common side effects
Key clinical trials
- The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity (PHASE4)
- Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine. (PHASE3)
- Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants (PHASE3)
- Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™
- Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210) (PHASE3)
- Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Rotarix dose 2) CI brief — competitive landscape report
- Placebo (for Rotarix dose 2) updates RSS · CI watch RSS
- University of Vermont portfolio CI